Sanja Prijić

Sanja Prijić

Auto-generated profile, based on publicly available information

Sanja Prijić

Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
SVSrdan Verstovsek
Srdan Verstovsek
TMTaghi Manshouri
Taghi Manshouri
DPDarrell Pilling
Darrell Pilling
CBCarlos E. Bueso-Ramos
Carlos E. Bueso-Ramos
KNKate J. Newberry
Kate J. Newberry
ZEZeev Estrov
Zeev Estrov
Primary myelofibrosis (PMF) is a fatal neoplastic disease characterized by clonal myeloproliferation and progressive bone marrow (BM) fibrosis thought to be induced by mesenchymal stromal cells stimulated by overproduced growth factors. However, tissue fibrosis in other diseases is associated with monocyte-derived fibrocytes. Therefore, we sought to determine whether fibrocytes play a role in the induction of BM fibrosis in PMF. In this study, we show that BM from patients with PMF harbors an abundance of clonal, neoplastic collagen- and fibronectin-producing fibrocytes. Immunodeficient mice transplanted with myelofibrosis patients’ BM cells developed a lethal myelofibrosis-like phenotype. Treatment of the xenograft mice with the fibrocyte inhibitor serum amyloid P (SAP; pentraxin-2) significantly prolonged survival and slowed the development of BM fibrosis. Collectively, our data suggest that neoplastic fibrocytes contribute to the induction of BM fibrosis in PMF, and inhibiting fibrocyte differentiation with SAP may interfere with this process.

29 December 2014 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SPSanja Prijić
Sanja Prijić
IUIvo Ugrina
Ivo Ugrina
BLBoris Labar
Boris Labar
DNDamir Nemet
Damir Nemet
JBJosip Batinić
Josip Batinić
DBDrago Batinić
Drago Batinić
Acute myeloid leukemia (AML) is a malignant hematopoietic disease with poor clinical course and outcome. There is a constant need for new prognostic factors that could facilitate patient risk stratification. The aim of our research was to determine the phosphorylation levels of phosphatidylinositol 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) pathways in leukemic cells, their relation to P-glycoprotein (P-gp) expression/activity and their prognostic significance in adult de novo AML. A total of 118 patients with AML were enrolled in the study. In a multivariate Cox regression analysis we found that P-gp activity and Akt phosphorylation were independent poor prognostic factors of overall survival (OS). In contrast, phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) represented a favorable prognostic factor of OS and relapse-free survival (RFS). A negative correlation between P-gp activity and p38 phosphorylation level was found, implying a possible role of this MAPK pathway in P-gp regulation. In addition, we found correlation between Akt and p38 phosphorylation levels, indicative of co-activation of two signaling cascades in AML.

1 June 2015 in Croatian Medical Journal
Verified
Journal Article
Open access
JBJosip Batinić
Josip Batinić
ZPZinaida Perić
Zinaida Perić
DŠDragana Šegulja
Dragana Šegulja
JLJames Last
James Last
SPSanja Prijić
Sanja Prijić
DNDamir Nemet
Damir Nemet
To evaluate the clinical utility of incorporating a novel heavy/light chain immunoassay (HLC) into the existing methods for the assessment of multiple myeloma (MM) patients.Convenience sera samples from 90 previously treated IgG and IgA MM patients in ...